Clinical Trial Update: Pacritinib in CMML [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicating Pacritinib is being studied for Chronic Myelomonocytic Leukemia in Phase 1/Phase 2 and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: Douglas Tremblay | Conditions: Chronic Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: RECRUITING